<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">To identify promising lead compounds for the drug development, it is important to select potential therapeutic targets for chronic HBV infection from the virus life cycle. Although various anti-HBV drugs, which is beyond the scope of this review, are the subject of preclinical and clinical trials,
 <sup>
  <xref ref-type="bibr" rid="CR64">64</xref>, 
  <xref ref-type="bibr" rid="CR65">65</xref>
 </sup> their inhibitory mechanisms should provide helpful data to make reasonable selections of such key targets for the drug screening for microbial products.
</p>
